Daily Archives: July 15, 2019

WillScot to Participate at the Jefferies Industrials Conference

BALTIMORE, July 15, 2019 (GLOBE NEWSWIRE) — WillScot Corporation (“WillScot”) (Nasdaq: WSC), the specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced that Brad Soultz, President and Chief Executive Officer, and Tim Boswell, Chief Financial Officer, will present at the Jefferies Industrials Conference in New York, on Wednesday, August 7, 2019.  The presentation will take place at 11:30 a.m. EDT.

About WillScot Corporation

Headquartered in Baltimore, Maryland, WillScot is the public holding company for the Williams Scotsman family of companies. WillScot trades on the Nasdaq stock exchange under the ticker symbol “WSC,” and is the specialty rental services market leader providing innovative modular space and portable storage solutions across North America. WillScot is the modular space supplier of choice for the construction, education, health care, government, retail, commercial, transportation, security and energy sectors. With over half a century of innovative history, organic growth and strategic acquisitions, WillScot serves a broad customer base from over 120 locations throughout the United States, Canada and Mexico, with a fleet of approximately 160,000 modular space and portable storage units.

Additional Information and Where to Find It

Additional information about WillScot can be found on its investor relations website: https://investors.willscot.com

Contact Information

Investor Inquiries:

Mark Barbalato
investors@willscot.com

Media Inquiries:

Scott Junk
scott.junk@willscot.com

Virtusa Achieves AWS Life Sciences Competency Status

Virtusa joins a group of AWS Partner Network members helping Life Sciences providers to deliver superior patient outcomes

SOUTHBOROUGH, Mass., July 15, 2019 (GLOBE NEWSWIRE) — Virtusa Corporation (NASDAQ GS: VRTU), a global provider of digital strategy, digital engineering, and IT outsourcing services that accelerates business outcomes for its clients, announced today that it has achieved Amazon Web Services (AWS) Life Sciences Competency status. This designation recognizes Virtusa for providing deep expertise in building Life Sciences solutions on AWS to help customers conduct drug discovery, manage clinical trials, engage in manufacturing and distribution activities, conduct research and development of novel genetic-based treatments and companion diagnostics.

Achieving the AWS Life Sciences Competency differentiates Virtusa as an AWS Partner Network (APN) member that has demonstrated relevant technical proficiency and proven customer success, delivering solutions seamlessly on AWS. To receive the designation, Virtusa demonstrated deep AWS expertise, significant Life Sciences domain knowledge and was assessed on the security, performance, and reliability of Virtusa solutions powered by AWS.

“Virtusa’s Life Sciences practice leverages AWS to harness the power of data for improved patient outcomes,” said Anthony Lange, senior vice president, Life Sciences, Virtusa.  Combining our deep life sciences expertise with powerful AWS next generation technology capabilities, we build software that helps deliver better patient outcomes at a lower cost. Achieving AWS Life Sciences Competency status will help more Virtusa clients in the Life Sciences industry achieve their business goals by leveraging the agility of AWS.”

Virtusa’s vLife platform, powered by AWS, has over one billion rows of clinical data providing Data, Analytics and Innovation as a Service. Virtusa offers pre-built solutions, AI/ML, and blockchain models to map patient journeys and disease progression.

AWS is enabling scalable, flexible, and cost-effective solutions from startups to global enterprises. To support the seamless integration and deployment of these solutions, AWS established the AWS Competency Program to help customers identify Consulting and Technology APN Partners with deep industry experience and expertise.

About Virtusa Corporation

Virtusa Corporation (NASDAQ GS: VRTU) is a global provider of digital business transformation, digital engineering, and information technology (IT) outsourcing services. Using a combination of digital strategy, business implementation, and IT platform modernization services, Virtusa helps clients drive profitable growth and lead market disruption through digital first client experiences. Founded in 1996 and headquartered in Southborough, Mass., Virtusa serves Global 2000 companies in the banking, financial services, insurance, healthcare, telecommunications, media, entertainment, travel, manufacturing and technology industries. For more information, visit: www.virtusa.com.

© 2019 Virtusa Corporation.  All rights reserved.

Virtusa, Accelerating Business Outcomes, BPM Test Drive, and Productization are registered trademarks of Virtusa Corporation.  All other company and brand names may be trademarks or service marks of their respective holders.

Contact:
Ron Favali
Conversion Marketing
ron@conversionam.com
727-512-4490

WSO2 Introduces WSO2 API Microgateway 3.0 to Simplify Creating, Deploying and Securing APIs in Microservice Environments

Newest release of the fully open source, cloud-native WSO2 API Microgateway adds new features to facilitate development and management while enabling greater scalability

Mountain View, CA and Portland, OR, July 15, 2019 (GLOBE NEWSWIRE) —

Microservices are rapidly becoming the de facto standard for modern software development. As a result, thousands of microservices are replacing hundreds of enterprise apps within an organization—driving exponential growth in the number of programmable endpoints handled by APIs. To simplify the process of creating, deploying and securing APIs within distributed microservices architectures, WSO2 has introduced several new features in version 3.0 of its fully open source WSO2 API Microgateway.

The availability of WSO2 API Microgateway 3.0 is being announced in conjunction with OSCON 2019, the O’Reilly Open Source Software Conference. WSO2, the world’s #1 open source integration vendor and an OSCON sponsor, will offer demos of the latest WSO2 API Microgateway release at the event. OSCON 2019 is being held July 15-18, 2019 at the Oregon Convention Center in Portland, OR.

WSO2 API Microgateway 3.0 for Easier Development, Greater Scalability
WSO2 API Microgateway is a cloud-native, lightweight, developer-centric, decentralized API gateway for microservices. It boots up in less than a second and features built-in capabilities for service-enrichment, such as authentication, authorization, rate limiting, service composition, discovery, transformation, and analytics. Using WSO2 API Microgateway, developers can compose microservices and expose them as APIs that operate in a range of deployments. These include Kubernetes clusters, containerized deployments, container management systems, service meshes, legacy deployments, and hybrid environments, among others.

WSO2 API Microgateway complements, and is integrated with, WSO2 API Manager, the leading open source software for full API lifecycle management, monetization, and policy enforcement. Part of the WSO2 Integration Agile Platform, WSO2 API Manager runs on-premises, in the cloud, and across hybrid environments to maximize deployment flexibility.

Version 3.0 of WSO2 API Microgateway adds several new features to facilitate API development and management while enabling greater scalability.

  • Developer-first runtime generation using the OpenAPI Specification (OAS) means developers can collaborate in creating APIs and then test them independently.
  • Run-time service discovery support allows the microgateway to automatically discover microservices, which often see IP address changes as a result of being redeployed.
  • Support for composing multiple microservices enables developers to expose a combination of microservices via a single API in line with modern best practices.
  • Support for transforming legacy API formats allows the microgateway to transform API requests and responses from legacy formats into modern ones, so they can be exposed to modern consumer apps.
  • Separation of the WSO2 API Microgateway toolkit from the runtime enables greater scalability and smoother upgrades.

The new functionality in WSO2 API Microgateway 3.0 builds on other key benefits delivered by the software. Because the microgateway can work in isolation with no dependencies on other components, it can scale up/down automatically with no impact on other resources. It also offers built-in support for container orchestration tools with the ability to generate Kubernetes artifacts based on configuration that can be applied directly to Kubernetes clusters. Additionally, WSO2 API Microgateway is DevOps friendly—taking APIs from development to test, staging and production, and featuring built-in capabilities for continuous integration/continuous development (CI/CD).

“API microgateways are a key part of building resilient, manageable microservices architectures,” said Paul Fremantle, WSO2 CTO and co-founder. “WSO2 API Microgateway 3.0 fits effectively into continuous development practices and has the proven scalability and robustness for mission-critical applications.”

Availability and Support
WSO2 API Microgateway 3.0 is available today. As a fully open source solution released under the Apache License 2.0, it does not carry any licensing fees. WSO2 API Microgateway is backed by WSO2 Subscription, which features access to WSO2 Update for continuous delivery of bug fixes, security updates, and performance enhancements, along with WSO2 Support for 24×7 support. Unified pricing means customers can simply buy a WSO2 Subscription and choose the hosting model—cloud, on-premises or hybrid—based on their preferences. Information on WSO2 Subscription and other service and support offerings can be found at https://wso2.com/consultant-services.

About WSO2
WSO2 is the world’s #1 open source integration vendor, helping digital-driven organizations become integration agile. Customers choose us for our broad integrated platform, our approach to open source, and our agile transformation methodology. The company’s hybrid platform for developing, reusing, running and managing integrations prevents lock-in through open source software that runs on-premises or in the cloud. Today, hundreds of leading brands and thousands of global projects execute 6 trillion transactions annually using WSO2 integration technologies. Visit https://wso2.com to learn more.

Shifali Erasmus
WSO2
650-544-6424
shifali@kineticprllc.com

Lubrizol Acquires Bavaria Medizin Technologie GmbH

The acquisition expands Lubrizol’s medical device design, development and manufacturing capabilities and adds expertise in drug-coated balloons and innovative catheter-based products

CLEVELAND, July 15, 2019 (GLOBE NEWSWIRE) — The Lubrizol Corporation announces the acquisition of Bavaria Medizin Technologie GmbH (BMT), an innovative designer and manufacturer of both intravascular (coronary, peripheral, and cranial) and nonvascular devices, including drug-coated balloons, by its German subsidiary Lubrizol Deutschland GmbH from its current majority shareholder Custos Vermögensverwaltungs GmbH as well as from the minority shareholders.

This acquisition builds upon Lubrizol’s expertise in precision thermoplastic extrusion and product development, establishing Lubrizol as a true end-to-end partner to the global medical device and pharmaceutical industries.

With over 100 employees, BMT is headquartered near Munich, Germany and operates a manufacturing facility in Sibiu, Romania. A pioneer in catheter-based technologies, BMT developed the first commercial drug-coated balloon, the Paccocath™ catheter. Today, BMT holds over 50 patents and continues to innovate through self-funded R&D projects, as well as contract R&D services. Additionally, BMT offers private label manufacturing of proprietary catheters and balloons along with original equipment manufacturing (OEM) services, which include the manufacturing of subassemblies and components, sterilization, packaging and labeling, stent crimping, and logistics management.

The acquisition of BMT expands Lubrizol’s product design, development, and manufacturing expertise and provides access to proprietary catheter and balloon technologies. BMT’s experience and reputation in the drug-coated balloon (DCB) space aligns well with Lubrizol’s pharmaceutical CDMO business and positions Lubrizol as the ideal partner for developing next generation DCBs.

“Lubrizol continues to invest in opportunities that position us as a full-service development partner for innovative OEMs in the interventional space,” said Uwe Winzen, general manager of the Health business of Lubrizol Life Science. “Our customers will benefit from additional design capabilities, an increased global footprint, and synergies with our existing formulation and manufacturing services.”

About Lubrizol Life Science – Health
The Health business team at Lubrizol Life Science partners with customers to speed their innovative medical devices and differentiated pharmaceutical products to market. Our dedicated team provides best-in-class polymers and excipients, along with state-of-the-art product design, development, and manufacturing services, with the ultimate goal of creating solutions that improve patient outcomes. For more information about the Health business of Lubrizol Life Science, visit www.Lubrizol.com/Life-Sciences.

About The Lubrizol Corporation
The Lubrizol Corporation, a Berkshire Hathaway company, is a market-driven global company that combines complex, specialty chemicals to optimize the quality, performance and value of customers’ products while reducing their environmental impact. It is a leader at combining market insights with chemistry and application capabilities to deliver valuable solutions to customers in the global transportation, industrial and consumer markets. Lubrizol improves lives by acting as an essential partner in our customers’ success, delivering efficiency, reliability or wellness to their end users. Technologies include lubricant additives for engine oils, driveline and other transportation-related fluids, industrial lubricants, as well as additives for gasoline and diesel fuel. In addition, Lubrizol makes ingredients and additives for home care, personal care and skin care products and specialty materials encompassing polymer and coatings technologies, along with polymer-based pharmaceutical and medical device solutions.

With headquarters in Wickliffe, Ohio, Lubrizol owns and operates manufacturing facilities in 17 countries, as well as sales and technical offices around the world. Founded in 1928, Lubrizol has approximately 8,700 employees worldwide. Revenues for 2018 were $6.8 billion. For more information, visit Lubrizol.com.

Media Contact
Nicholas DiFranco
(216) 447-6728
Nicholas.DiFranco@lubrizol.comWebsite: www.lubrizol.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/249896f6-1da6-4a32-9091-c7e3d5c33bd0